Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Compass Pathways (NASDAQ: CMPS), a biotechnology company focused on mental health innovation, has announced it will release its Q4 and full-year 2024 financial results on February 27th, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) on the same day to discuss results and provide updates on recent developments. Investors can access the call through pre-registration, and a live webcast will be available on the company's website. The webcast recording will remain accessible for 30 days in the Investors section.
Compass Pathways (NASDAQ: CMPS), un'azienda biotecnologica focalizzata sull'innovazione nella salute mentale, ha annunciato che pubblicherà i suoi risultati finanziari per il Q4 e l'intero anno 2024 il 27 febbraio 2025. L'azienda ospiterà una conferenza telefonica alle 8:00 AM ET (1:00 PM UK) lo stesso giorno per discutere i risultati e fornire aggiornamenti sugli sviluppi recenti. Gli investitori possono accedere alla chiamata tramite pre-registrazione, e una trasmissione in diretta sarà disponibile sul sito web dell'azienda. La registrazione della trasmissione rimarrà accessibile per 30 giorni nella sezione Investitori.
Compass Pathways (NASDAQ: CMPS), una empresa biotecnológica centrada en la innovación en salud mental, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 27 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica a las 8:00 AM ET (1:00 PM UK) el mismo día para discutir los resultados y proporcionar actualizaciones sobre los desarrollos recientes. Los inversores pueden acceder a la llamada a través de un registro previo, y se dispondrá de una transmisión en vivo en el sitio web de la empresa. La grabación de la transmisión estará disponible durante 30 días en la sección de Inversores.
Compass Pathways (NASDAQ: CMPS), 정신 건강 혁신에 초점을 맞춘 생명공학 회사가 2024년 4분기 및 연간 재무 결과를 2025년 2월 27일에 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오전 8시 (영국 오후 1시)에 결과를 논의하고 최근 개발에 대한 업데이트를 제공하기 위한 전화 회의를 개최합니다. 투자자는 사전 등록을 통해 전화를 이용할 수 있으며, 회사 웹사이트에서 실시간 웹캐스트를 이용할 수 있습니다. 웹캐스트 녹화는 투자자 섹션에서 30일 동안 접근할 수 있습니다.
Compass Pathways (NASDAQ: CMPS), une entreprise de biotechnologie axée sur l'innovation en santé mentale, a annoncé qu'elle publiera ses résultats financiers du 4ème trimestre et de l'année 2024 le 27 février 2025. L'entreprise organisera une conférence téléphonique le même jour à 8h00 ET (13h00 UK) pour discuter des résultats et fournir des mises à jour sur les développements récents. Les investisseurs peuvent accéder à l'appel par préinscription, et un webinaire en direct sera disponible sur le site web de l'entreprise. L'enregistrement du webinaire sera accessible pendant 30 jours dans la section Investisseurs.
Compass Pathways (NASDAQ: CMPS), ein Biotechnologieunternehmen, das sich auf Innovationen im Bereich der psychischen Gesundheit konzentriert, hat bekannt gegeben, dass es seine Finanzergebnisse für das 4. Quartal und das gesamte Jahr 2024 am 27. Februar 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:00 Uhr ET (13:00 Uhr UK) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Updates zu aktuellen Entwicklungen zu geben. Investoren können über eine Voranmeldung auf die Konferenz zugreifen, und ein Live-Webcast wird auf der Website des Unternehmens verfügbar sein. Die Aufzeichnung des Webcasts bleibt 30 Tage lang im Bereich Investoren zugänglich.
- None.
- None.
Compass management will host a conference call at 8:00 am ET (1:00pm
Compass management will host a conference call at 8:00 am ET (1:00pm
A live webcast of the call will be available on the Compass Pathways website at: Fourth Quarter 2024 Financial Results
The webcast will also be available on the Investors section of Compass Pathways website. The webcast will be archived for 30 days.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthesized psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa.
Compass is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218839117/en/
Enquiries
Media: media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Source: Compass Pathways plc
FAQ
When will Compass Pathways (CMPS) release Q4 2024 financial results?
What time is the CMPS Q4 2024 earnings conference call?
How can investors access the CMPS Q4 2024 earnings call?
How long will the CMPS Q4 2024 earnings webcast be available?
